| 1 | Prognostic value of proliferation, PD-L1 and nuclear size in patients with superior sulcus tumours treated with chemoradiotherapy and surgery | 2.0 | 2 | Citations (PDF) |
| 2 | Diagnosis of atypical carcinoid can be made on biopsies > 4 mm2 and is accurate | 3.0 | 10 | Citations (PDF) |
| 3 | The impact of a pathologist’s personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer | 2.7 | 28 | Citations (PDF) |
| 4 | The evolving landscape of biomarker testing for non-small cell lung cancer in Europe | 2.7 | 178 | Citations (PDF) |
| 5 | RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer | 2.2 | 38 | Citations (PDF) |
| 6 | Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project | 2.2 | 59 | Citations (PDF) |
| 7 | <scp>COVID</scp>‐19: Histopathological correlates of imaging patterns on chest <scp>computed tomography</scp> | 4.1 | 28 | Citations (PDF) |
| 8 | Polarization-sensitive optical coherence tomography in end-stage lung diseases: an ex vivo pilot study | 2.9 | 9 | Citations (PDF) |
| 9 | Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization | 2.5 | 30 | Citations (PDF) |
| 10 | PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee | 2.2 | 281 | Citations (PDF) |
| 11 | External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different | 3.4 | 31 | Citations (PDF) |
| 12 | Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer | 2.0 | 17 | Citations (PDF) |
| 13 | Morphologic Logic: “Filigree” and “Classical” Micropapillary Pattern Are Orientation-Dependent Views of the Same Lesion | 2.2 | 6 | Citations (PDF) |
| 14 | Lung cancer biomarker testing: perspective from Europe | 2.1 | 29 | Citations (PDF) |
| 15 | RE: Spread Through Air Spaces (STAS) is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung | 2.2 | 3 | Citations (PDF) |
| 16 | Pathologists should probably forget about kappa. Percent agreement, diagnostic specificity and related metrics provide more clinically applicable measures of interobserver variability | 1.2 | 28 | Citations (PDF) |
| 17 | Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non–Small-Cell Lung Cancer | 2.6 | 9 | Citations (PDF) |
| 18 | Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples | 3.1 | 3 | Citations (PDF) |
| 19 | Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy | 5.7 | 42 | Citations (PDF) |
| 20 | Tumor Atelectasis Gives Rise to a Solid Appearance in Pulmonary Adenocarcinomas on High-Resolution Computed Tomography | 1.0 | 2 | Citations (PDF) |
| 21 | The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee | 2.2 | 254 | Citations (PDF) |
| 22 | A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee | 2.2 | 455 | Citations (PDF) |
| 23 | Quantification of PD-L1 Expression with <sup>18</sup>F-BMS-986192 PET/CT in Patients with Advanced-Stage Non–Small Cell Lung Cancer | 5.6 | 71 | Citations (PDF) |
| 24 | IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy | 2.2 | 372 | Citations (PDF) |
| 25 | Influence of preanalytical variables on performance of delta-like protein 3 (DLL3) predictive immunohistochemistry | 3.0 | 2 | Citations (PDF) |
| 26 | In Reply | 2.5 | 1 | Citations (PDF) |
| 27 | Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen | 3.0 | 54 | Citations (PDF) |
| 28 | Clonality analysis of pulmonary tumors by genome-wide copy number profiling | 2.4 | 12 | Citations (PDF) |
| 29 | A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project | 2.7 | 45 | Citations (PDF) |
| 30 | Gross handling of pulmonary resection specimen: maintaining the 3-dimensional orientation | 1.3 | 22 | Citations (PDF) |
| 31 | A Population-Based Study of Outcomes in Surgically Resected T3N0 Non–Small Cell Lung Cancer in The Netherlands, Defined Using TNM-7 and TNM-8; Justification of Changes and an Argument to Incorporate Histology in the Staging Algorithm | 2.2 | 18 | Citations (PDF) |
| 32 | Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction | 2.4 | 28 | Citations (PDF) |
| 33 | How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non–Small Cell Lung Cancer | 2.5 | 18 | Citations (PDF) |
| 34 | Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens? | 3.7 | 42 | Citations (PDF) |
| 35 | Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort | 4.9 | 31 | Citations (PDF) |
| 36 | Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology | 2.5 | 728 | Citations (PDF) |
| 37 | Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung | 2.2 | 47 | Citations (PDF) |
| 38 | Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project | 2.2 | 79 | Citations (PDF) |
| 39 | Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients | 6.9 | 84 | Citations (PDF) |
| 40 | Rapid On-Site Evaluation of Endobronchial Ultrasound–Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society | 2.5 | 155 | Citations (PDF) |
| 41 | Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society | 2.5 | 74 | Citations (PDF) |
| 42 | Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma | 2.2 | 228 | Citations (PDF) |
| 43 | PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project | 2.2 | 708 | Citations (PDF) |
| 44 | Pulmonary loose tumor tissue fragments and spread through air spaces (STAS): Invasive pattern or artifact? A critical review | 2.7 | 41 | Citations (PDF) |
| 45 | Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH | 2.2 | 8 | Citations (PDF) |
| 46 | DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2 years | 2.0 | 25 | Citations (PDF) |
| 47 | The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases | 2.2 | 130 | Citations (PDF) |
| 48 | PD-L1 IHC in NSCLC with a global and methodological perspective | 2.7 | 41 | Citations (PDF) |
| 49 | Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project | 2.7 | 71 | Citations (PDF) |
| 50 | Reply to Letter “The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases.” | 2.2 | 5 | Citations (PDF) |
| 51 | Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens | 8.7 | 96 | Citations (PDF) |
| 52 | Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer | 1.7 | 194 | Citations (PDF) |
| 53 | Ex Vivo Artifacts and Histopathologic Pitfalls in the Lung | 2.5 | 91 | Citations (PDF) |
| 54 | Testing for ROS1 in non-small cell lung cancer: a review with recommendations | 3.0 | 213 | Citations (PDF) |
| 55 | Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC | 2.7 | 30 | Citations (PDF) |
| 56 | A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors | 2.2 | 13 | Citations (PDF) |
| 57 | Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group | 5.8 | 180 | Citations (PDF) |
| 58 | Clinical features of large cell neuroendocrine carcinoma: a population-based overview | 12.1 | 115 | Citations (PDF) |
| 59 | Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL | 3.0 | 97 | Citations (PDF) |
| 60 | Detecting Resistance in
<i>Egfr</i>
-Mutated Non-Small-Cell Lung Cancer After Clonal Selection Through Targeted Therapy | 1.4 | 2 | Citations (PDF) |
| 61 | Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer? | 2.7 | 7 | Citations (PDF) |
| 62 | Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis | 2.7 | 127 | Citations (PDF) |
| 63 | Comprehensive genomic profiles of small cell lung cancer | 38.7 | 2,103 | Citations (PDF) |
| 64 | Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions | 12.2 | 44 | Citations (PDF) |
| 65 | Diagnostic challenges in survivors of early stage lung cancer | 2.7 | 3 | Citations (PDF) |
| 66 | Towards a close computed tomography monitoring approach for screen detected subsolid pulmonary nodules? | 12.1 | 116 | Citations (PDF) |
| 67 | Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis? | 1.5 | 5 | Citations (PDF) |
| 68 | The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization | 2.4 | 29 | Citations (PDF) |
| 69 | Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis | 2.0 | 63 | Citations (PDF) |
| 70 | Guidance for laboratories performing molecular pathology for cancer patients | 2.0 | 188 | Citations (PDF) |
| 71 | Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study | 2.2 | 38 | Citations (PDF) |
| 72 | Prognostic and predictive biomarkers in lung cancer. A review | 3.0 | 80 | Citations (PDF) |
| 73 | Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology | 4.2 | 45 | Citations (PDF) |
| 74 | Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers | 26.0 | 348 | Citations (PDF) |
| 75 | Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus | 3.0 | 21 | Citations (PDF) |
| 76 | EGFR mutation analysis in sputum of lung cancer patients: A multitechnique study | 2.7 | 35 | Citations (PDF) |
| 77 | Characteristics of Lung Cancers Detected by Computer Tomography Screening in the Randomized NELSON Trial | 12.2 | 249 | Citations (PDF) |
| 78 | Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology | 2.5 | 427 | Citations (PDF) |
| 79 | Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial | 12.1 | 219 | Citations (PDF) |
| 80 | Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification | 2.5 | 390 | Citations (PDF) |
| 81 | Reproducibility of Immunohistochemical Scoring for Epidermal Growth Factor Receptor Expression in Non–Small Cell Lung Cancer: Round Robin Test | 2.5 | 26 | Citations (PDF) |
| 82 | Tumor size does not predict pathological complete response rates after pre-operative chemoradiotherapy for non-small cell lung cancer | 1.8 | 2 | Citations (PDF) |
| 83 | In Compressed Lung Tissue Microscopic Sections of Adenocarcinoma In Situ May Mimic Papillary Adenocarcinoma | 2.5 | 25 | Citations (PDF) |
| 84 | Diagnosis of Lung Adenocarcinoma in Resected Specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification | 2.5 | 159 | Citations (PDF) |
| 85 | CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids | 6.9 | 95 | Citations (PDF) |
| 86 | A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a <i>KRAS</i> Mutation | 6.9 | 77 | Citations (PDF) |
| 87 | Development of [11C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status | 6.9 | 120 | Citations (PDF) |
| 88 | KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value | 2.2 | 43 | Citations (PDF) |
| 89 | Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3′-Deoxy-3′-[18F]fluorothymidine Positron Emission Tomography | 2.4 | 20 | Citations (PDF) |
| 90 | Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer | 2.0 | 20 | Citations (PDF) |
| 91 | An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? | 2.2 | 3 | Citations (PDF) |
| 92 | Negative NKX2-1 (TTF-1) as Temporary Surrogate Marker for Treatment Selection During EGFR-Mutation Analysis in Patients with Non–Small-Cell Lung Cancer | 2.2 | 26 | Citations (PDF) |
| 93 | Applying Biomarker Testing to Clinical Practice in Lung Cancer | 0.6 | 0 | Citations (PDF) |
| 94 | KRAS and BRAF Mutation Analysis in Routine Molecular Diagnostics | 2.6 | 53 | Citations (PDF) |
| 95 | Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study | 4.9 | 231 | Citations (PDF) |
| 96 | EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations | 3.0 | 204 | Citations (PDF) |
| 97 | Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma | 3.0 | 32 | Citations (PDF) |
| 98 | The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group | 2.7 | 223 | Citations (PDF) |
| 99 | Guideline on the requirements of external quality assessment programs in molecular pathology | 3.0 | 73 | Citations (PDF) |
| 100 | A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation | 1.5 | 21 | Citations (PDF) |
| 101 | Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin | 6.9 | 96 | Citations (PDF) |
| 102 | EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy | 2.0 | 32 | Citations (PDF) |
| 103 | International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma | 2.2 | 4,574 | Citations (PDF) |
| 104 | Bronchioloalveolar Adenocarcinoma and Pulmonary Langerhans Cell Histiocytosis in a Patient With <i>MUTYH</i>-Associated Polyposis | 21.6 | 6 | Citations (PDF) |
| 105 | Frequent and Focal
<i>FGFR1</i>
Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer | 12.7 | 790 | Citations (PDF) |
| 106 | Management of Lung Nodules Detected by Volume CT Scanning | 43.7 | 795 | Citations (PDF) |
